12:00 AM
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aeroquin: Phase III data

The double-blind, international Phase III 207 trial in 330 CF patients with P. aeruginosa infection showed that twice-daily 240 mg Aeroquin for 28 days missed the primary endpoint of improving time to first pulmonary exacerbation vs. placebo. Aptalis said Aeroquin "demonstrated efficacy" on certain secondary endpoints,...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >